## Rita Shaknovich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11292588/publications.pdf

Version: 2024-02-01

80 papers

7,128 citations

39 h-index 95266 68 g-index

82 all docs 82 docs citations

times ranked

82

10292 citing authors

#	Article	IF	CITATIONS
1	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 2020, 31, 745-759.	1.2	770
2	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
3	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nature Medicine, 2015, 21, 1199-1208.	30.7	359
4	Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood, 2008, 111, 1515-1523.	1.4	269
5	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood, 2010, 116, 5247-5255.	1.4	262
6	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL InÂVitro and InÂVivo. Cancer Cell, 2012, 22, 812-824.	16.8	229
7	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	9.4	218
8	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood, 2009, 113, 5536-5548.	1.4	205
9	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell, 2016, 30, 197-213.	16.8	200
10	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. Cancer Discovery, 2013, 3, 1002-1019.	9.4	180
11	Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene, 1999, 18, 925-934.	5.9	177
12	TET1 is a tumor suppressor of hematopoietic malignancy. Nature Immunology, 2015, 16, 653-662.	14.5	173
13	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. Molecular and Cellular Biology, 1998, 18, 5533-5545.	2.3	164
14	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood, 2009, 113, 3397-3405.	1.4	154
15	CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer. Cell Reports, 2014, 7, 1020-1029.	6.4	154
16	Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood, 2006, 107, 3967-3975.	1.4	151
17	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. Cell, 2011, 147, 554-564.	28.9	151
18	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas. Nature Medicine, 2009, 15, 1369-1376.	30.7	149

#	Article	IF	Citations
19	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 2010, 116, 1025-1034.	1.4	138
20	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood, 2010, 116, e81-e89.	1.4	138
21	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. Journal of Clinical Investigation, 2016, 126, 3351-3362.	8.2	133
22	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood, 2011, 118, 3559-3569.	1.4	123
23	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer Discovery, 2018, 8, 1632-1653.	9.4	120
24	Stages of Germinal Center Transit Are Defined by B Cell Transcription Factor Coexpression and Relative Abundance. Journal of Immunology, 2006, 177, 6930-6939.	0.8	119
25	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	1.4	117
26	Epigenomic evolution in diffuse large B-cell lymphomas. Nature Communications, 2015, 6, 6921.	12.8	111
27	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. PLoS Genetics, 2013, 9, e1003137.	3.5	102
28	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Journal of Clinical Investigation, 2010, 120, 4569-4582.	8.2	101
29	PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. Journal of Pathology, 2005, 206, 76-86.	4.5	97
30	SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood, 2011, 118, 6342-6352.	1.4	93
31	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports, 2015, 12, 2086-2098.	6.4	87
32	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood, 2014, 123, 1699-1708.	1.4	83
33	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology, 2019, 20, 86-96.	14.5	71
34	Downregulation of FOXP1 is required during germinal center B-cell function. Blood, 2013, 121, 4311-4320.	1.4	62
35	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. Clinical Cancer Research, 2021, 27, 4221-4229.	7.0	61
36	Epigenetics and B-cell lymphoma. Current Opinion in Hematology, 2011, 18, 293-299.	2.5	60

#	Article	IF	CITATIONS
37	Requirement for cyclin D3 in germinal center formation and function. Cell Research, 2010, 20, 631-646.	12.0	55
38	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nature Communications, 2018, 9, 222.	12.8	51
39	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers, 2021, 13, 3501.	3.7	50
40	Down-Regulation of elF4GII by miR-520c-3p Represses Diffuse Large B Cell Lymphoma Development. PLoS Genetics, 2014, 10, e1004105.	<b>3.</b> 5	39
41	SOX11 augments BCR signaling to drive MCL-like tumor development. Blood, 2018, 131, 2247-2255.	1.4	37
42	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. Journal of Clinical Investigation, 2015, 125, 4559-4571.	8.2	37
43	Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood, 2013, 121, 4271-4279.	1.4	32
44	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. Cancer Research, 2008, 68, 3361-3369.	0.9	30
45	Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2012, 51, 1125-1132.	2.8	29
46	Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. Nucleic Acids Research, 2015, 43, 5307-5317.	14.5	28
47	HELP (Hpall Tiny Fragment Enrichment by Ligation-Mediated PCR) Assay for DNA Methylation Profiling of Primary Normal and Malignant B Lymphocytes. Methods in Molecular Biology, 2010, 632, 191-201.	0.9	26
48	Epigenetic Function of Activation-Induced Cytidine Deaminase and Its Link to Lymphomagenesis. Frontiers in Immunology, 2014, 5, 642.	4.8	25
49	GobyWeb: Simplified Management and Analysis of Gene Expression and DNA Methylation Sequencing Data. PLoS ONE, 2013, 8, e69666.	2.5	25
50	Novel Relational Database for Tissue Microarray Analysis. Archives of Pathology and Laboratory Medicine, 2003, 127, 492-494.	2.5	24
51	Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood, 2018, 132, e13-e23.	1.4	23
52	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. Blood, 2013, 122, 1-1.	1.4	23
53	Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica, 2006, 91, 1313-20.	3 <b>.</b> 5	18
54	Epigenetic diversity in hematopoietic neoplasms. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 477-484.	7.4	11

#	Article	IF	CITATIONS
55	The new frontier of epigenetic heterogeneity in B-cell neoplasms. Current Opinion in Hematology, 2017, 24, 402-408.	2.5	11
56	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures Blood, 2009, 114, 619-619.	1.4	10
57	A rare cause of nephrotic syndrome. American Journal of Kidney Diseases, 2002, 39, 892-895.	1.9	9
58	Epigenetic Determinants of Pathogenesis and Resistance to Proteosome Inhibition in Mantle Cell Lymphoma Blood, 2008, 112, 3373-3373.	1.4	8
59	Characterization of DLBCL-Derived Exosomes and Investigation of Their Biological Properties. Blood, 2014, 124, 3021-3021.	1.4	8
60	Gene Expression and Epigenetic Deregulation. Advances in Experimental Medicine and Biology, 2013, 792, 133-150.	1.6	5
61	Constitutively Activated STAT3 Promotes Cell Proliferation and Survival in the Activated B Cell Subtype of Diffuse Large B Cell Lymphomas Blood, 2007, 110, 1621-1621.	1.4	3
62	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. Blood, 2013, 122, 634-634.	1.4	2
63	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis Blood, 2009, 114, 3465-3465.	1.4	2
64	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted Blood, 2006, 108, 225-225.	1.4	1
65	DNA Methyltransferase 1 Contributes to Epigenetic Signatures and Biological Phenotype during Normal B-Cell Differentiation and Lymphomagenesis Blood, 2007, 110, 685-685.	1.4	1
66	Demethylase Activity of Aid during Germinal Center B Cell Maturation Could Contribute to Lymphomagenesis. Blood, 2014, 124, 59-59.	1.4	1
67	SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis. Blood, 2015, 126, 1253-1253.	1.4	1
68	Protein Signature of LMP1 Signaling in PTLDs Identifies and Mimics Inter/Perifollicular CD30+ EBVâ^' B Blasts Blood, 2004, 104, 3251-3251.	1.4	0
69	BCL6 Regulates Diffuse Large B-Cell Lymphoma Cell Cycle and Apoptosis Checkpoints through Direct Repression of the p300 Histone Acetyl-Transferase Blood, 2006, 108, 1413-1413.	1.4	0
70	Cyclin D3 Is Required for the Germinal Center Reaction. Blood, 2008, 112, 2580-2580.	1.4	0
71	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy Blood, 2009, 114, 673-673.	1.4	0
72	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. Blood, 2011, 118, 1617-1617.	1.4	0

#	Article	IF	CITATIONS
73	Differential DNA Methylation of TUBB1 Correlates with Tissue-Specific $H\hat{I}^2$ -1 Tubulin Expression. Blood, 2011, 118, 4796-4796.	1.4	O
74	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. Blood, 2011, 118, 556-556.	1.4	0
75	Epigenetic Profiling of Primary CLL Reveals Novel DNA Methylation-Based Clusters and Novel Mechanisms of Leukemogenesis. Blood, 2012, 120, 3877-3877.	1.4	O
76	IL10 Receptor a Is a Novel Therapeutic Target That Is Epigenetically Disregulated in Low Grade Lymphomas with Plasmacytic Differentiation Blood, 2012, 120, 2383-2383.	1.4	0
77	Three-Dimensional Reorganization of the Genome During B Cell Affinity Maturation. Blood, 2012, 120, 279-279.	1.4	O
78	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. Blood, 2014, 124, 2963-2963.	1.4	O
79	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. Blood, 2015, 126, 434-434.	1.4	0
80	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	1.4	O